|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||251.79 - 254.30|
|52 Week Range||208.62 - 265.87|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||75.93|
|Forward Dividend & Yield||3.08 (1.22%)|
|1y Target Est||N/A|
The size of Becton, Dickinson and Company (NYSE:BDX), a US$68b large-cap, often attracts investors seeking a reliable...
David King spent the bulk of his entire career turning around mutual funds, but now he runs a fund of his own design, the Columbia Flexible Capital Income fund.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Becton, Dickinson and Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Becton Dickinson and Co NYSE:BDXView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BDX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BDX are favorable, with net inflows of $9.79 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BDX credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Becton, Dickinson and Company (NYSE:BDX) saw significant share price movement during recent months on the NYSE, rising...
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dividend paying stocks like Becton, Dickinson and Company (NYSE:BDX) tend to be popular with investors, and for good...
Moody's Investors Service ("Moody's") today assigned Ba1 ratings to the senior unsecured notes to be offered by Becton Dickinson Euro Finance S.a.r.l. As part of the refinancing, BD plans to repay at maturity its euro 1 billion notes due in June 2019 and to tender for certain other outstanding notes of BD.
Moody's Investors Service ("Moody's") today affirmed all of Becton, Dickinson & Company's ("BD") ratings including the Ba1 Corporate Family Rating, Ba1-PD Probability of Default Rating, Not Prime commercial paper rating, SGL-1 Speculative Grade Liquidity rating and the Ba1 senior unsecured rating. "The revision in the outlook to positive considers the deleveraging progress that BD has made since the closing of the Bard acquisition in December 2017" said Moody's Senior Vice President Scott Tuhy.
In this daily bar chart of BDX, below, we can see that prices made a peak in early October and prices weakened into late December/early January. The daily On-Balance-Volume (OBV) line has declined since early April and suggests that sellers of BDX have been more aggressive. In this weekly bar chart of BDX, below, we can see a potential topping or bearish pattern from late 2017 with a possible "neckline" across the $210 level.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would hold off for now from Village Farms International Inc (NASDAQ: VFF ). He is not a buyer of Sailpoint Technologies Holdings Inc ...
Becton Dickinson and Co’s (NYSE: BDX ) stock has lost more than 10 percent since March 15 in response to the FDA update on drug-coated balloons, or DCBs. The market seems to have overreacted to the news, ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Shares of Becton Dickinson & Co. dropped 3.1% in morning trade Thursday, after the medical technology company topped fiscal second-quarter profit expectations, but slashed its full-year outlook, citing "recent regulatory and market pressures related to paclitaxel-coated devices." The net loss for the latest quarter narrowed to $18 million, or 7 cents a share, from $50 million, or 19 cents a share, in the same period a year ago. Adjusted EPS, which excludes non-recurring items, fell 2.3% to $2.59, but topped the FactSet consensus of $2.58. Revenue declined 0.6% to $4.195 billion, just shy of the FactSet consensus of $4.238 billion. For fiscal 2019, the company cut its adjusted EPS guidance range to $11.65 to $11.75 from $12.05 to $12.15. The company also lowered its revenue growth outlook to 8.0% to 9.0% from 8.5% to 9.5%, citing an estimated additional negative impact from currency moves. The stock has now slipped 0.1% year to date, while the SPDR Health Care Select Sector ETF has gained 2.3% and the S&P 500 has tacked on 13.8%.